{"schema_version":"secwatch.filing_event.v1","accession":"0001501697-26-000081","form_type":"8-K","ticker":"XFOR","cik":"0001501697","company_name":"X4 Pharmaceuticals, Inc","filed_at":"2026-10-08T21:23:01+00:00","discovered_at":"2026-10-08T21:24:00.359823+00:00","generated_at":"2026-10-12T15:21:52.631586+00:00","sec_items":["1.01","1.02","2.03","3.02","7.01","9.01"],"event_type":"debt","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"X4 Pharma secures up to $150M K2 HealthVentures loan; repays $78.7M Hercules debt, interest-only to Oct 2029","bullets":["$80M first tranche funded at closing repaid Hercules' ~$78.7M payoff ($75M principal, interest, end-of-term and prepayment charges); up to $70M second tranche needs K2HV approval.","Term loans bear interest at the greater of 8.55% or WSJ prime +1.55%, plus 1.0% paid-in-kind interest; interest-only through Oct 1, 2029, maturing Oct 1, 2030.","Interest-only period extends to maturity if X4 achieves first U.S. commercial sales of mavorixafor in moderate to severe chronic neutropenia; K2HV may convert up to $15M into stock at $3.2341.","Covenants from Oct 1, 2027: if market cap <$800M, unrestricted cash must cover 75% of obligations (40% after conditions); from Apr 1, 2029, trailing 3-month revenue ≥50% of board projections.","X4 expects to complete enrollment in the Phase 3 4WARD trial by year-end 2026 with topline data in H1 2028; loan is secured by substantially all assets excluding intellectual property."],"urls":{"canonical":"https://secwatch.observer/filing/0001501697-26-000081","json":"https://secwatch.observer/filing/0001501697-26-000081.json","markdown":"https://secwatch.observer/filing/0001501697-26-000081.md","text":"https://secwatch.observer/filing/0001501697-26-000081.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1501697/000150169726000081/0001501697-26-000081-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1501697/000150169726000081/xfor-20261007.htm"},"model":{"generated_by":"deepseek-v4.1-flash:cloud@v2","generated_at":"2026-10-12T15:21:52.631586+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}